Congress Coverage: EHA 2021 – Focus on Leukemia and MDS

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia

June 25, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Faculty Members

Charles Craddock, CBE, FRCP, FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK

Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA

Nicola Gökbuget, MD 
University Hospital Frankfurt, Frankfurt am Main, Germany

Gert Ossenkoppele, MD, PhD
VU University Medical Center Amsterdam , Amsterdam, the Netherlands

Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX, USA

Jae Park, MD
Memorial Sloan Kettering, New York, NY, USA

Philippe Rousselot, MD, PhD
Versailles Hospital Center, Le Chesnay-Rocquencourt, France

Valeria Santini, MD
University of Florence, Firenze, Italy

Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Sample Report

Start discovering the insights

View Report


  • Updates on MDS
  • Newly diagnosed AML patients
  • IDH1/2 and FLT3 mutations in newly diagnosed AML patients
  • FLT3 mutations in relapsed/refractory AML patients
  • IDH1/2 mutations in relapsed/refractory AML patients
  • Updates in ALL

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.